Clinical Trial Update: Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer; the study status is active but not cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: University of Sydney | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING